Most investors grow up hearing the same financial advice. Study […]
Weight loss drugs entered a price war. Novo Nordisk launched high-dose Wegovy (7.2mg) at $399 monthly for paying patients - 40% cheaper than Eli Lilly's comparable Zepbound doses.
Standard Wegovy produces roughly 15% weight loss. High-dose achieves 20.7% over 72 weeks. That difference moves from noticeable to transformative.
At $399 monthly, Novo undercuts Eli Lilly by 40%. Over one year of treatment, patients save hundreds of dollars.
High-dose Wegovy launches at 70,000+ US pharmacies on April 8. The FDA approved it on March 19 through priority voucher review.
Insurance coverage decisions matter most. If insurers cover high-dose Wegovy as first-line treatment, Novo could dominate the weight loss market for years.
Most investors grow up hearing the same financial advice. Study […]
The tax code in the United States is over 2,000 […]
Most banks pay you almost nothing to hold your money. […]
Most investors start their journey the same way. They Google […]
Warren Buffett earned $704 million in dividends in 2021. His […]
You wouldn't buy a house without looking at the inspection […]
You've decided you want to start investing. You open your […]
You check your portfolio one morning and see red everywhere. […]
Investing is not a one size fits all approach. Some […]
Everyone with an internet connection is using AI to better […]
